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Adrenalectomy Alters the Sensitivity of the Central
Nervous System Melanocortin System
Deborah L. Drazen,1 Matthew D. Wortman,1 Michael W. Schwartz,2 Deborah J. Clegg,1
Gertjan van Dijk,3 Stephen C. Woods,1 and Randy J. Seeley1
Removal of adrenal steroids by adrenalectomy (ADX)
reduces food intake and body weight in rodents and
prevents excessive weight gain in many genetic and
dietary models of obesity. Thus, glucocorticoids appear
to play a key role to promote positive energy balance in
normal and pathological conditions. By comparison,
central nervous system melanocortin signaling provides
critical inhibitory tone to regulate energy balance. The
present experiments sought to test whether glucocorti-
coids influence energy balance by altering the sensi-
tivity to melanocortin receptor ligands. Because
melanocortin-producing neurons are hypothesized to be
downstream of leptin in a key weight-reducing circuit,
we tested rats for their sensitivity to leptin and con-
firmed reports that the hypophagic response to third
ventricular (i3vt) leptin is increased in ADX rats and is
normalized by glucocorticoid replacement. Next we
tested rats for their sensitivity to the melanocortin
agonist melanotan II and found that, as for leptin, ADX
enhanced the hypophagic response via a glucocorticoid-
dependent mechanism. The central nervous system
melanocortin system is unique in that it includes the
endogenous melanocortin receptor antagonist, AgRP.
The orexigenic effect of i3vt AgRP was absent in ADX
rats and restored by glucocorticoid replacement. We
conclude that the potent weight-reducing effects of ADX
likely involve heightened responsiveness to melanocor-
tin receptor stimulation. Diabetes 52:2928–2934, 2003
Obesity is a major risk factor for many diseases,including diabetes, hypertension, cardiovascu-lar disease, and some cancers. Among themyriad factors mediating the regulation of food
intake and body weight is the glucocorticoid, cortisol
(corticosterone in rats), which is secreted from the adre-
nal cortex. Glucocorticoids are lipophilic molecules that
freely cross the blood-brain barrier and interact with
receptors distributed throughout the central nervous sys-
tem, including the hypothalamus (1). In rodents, most
forms of genetic obesity are associated with increased
glucocorticoid levels, whereas a lack of glucocorticoids is
linked to hypophagia and reduced body weight. Parallels
exist in humans as well. Individuals with Addison’s disease
exhibit anorexia and weight loss due to adrenal insuffi-
ciency, whereas patients with Cushing’s disease and other
glucocorticoid excess syndromes have increased food
intake (2) and visceral adiposity. In rodents, adrenalec-
tomy (ADX) reverses many forms of obesity, while glu-
cocorticoid replacement restores the obese state (2), and
glucocorticoid administration to adrenal-intact animals
increases food intake and weight gain (2,3).
Whereas glucocorticoids stimulate food intake and
weight gain, leptin is a hormone that provides negative
feedback in the control of food intake and adiposity.
Leptin is secreted from adipocytes in direct proportion to
the amount of stored fat (4,5), and plasma leptin levels fall
during caloric restriction and rise during overfeeding
(4,6–8). Genetic leptin deficiency results in profound
hyperphagia and obesity in mice and humans (9), a syn-
drome that can be reversed by exogenous leptin treatment
(10–12). These effects of leptin are due to activation of the
leptin receptor in brain regions important for body weight
regulation (5), including the hypothalamic arcuate nucleus
(ARC) and adjacent areas (13).
Several lines of evidence suggest an interaction between
leptin and the hypothalamic-pituitary-adrenal axis (14).
Genetic deficiency of leptin or its receptor is characterized
by hypercorticosteronemia in rodents (15); in leptin-defi-
cient ob/ob mice, leptin replacement decreases corticoste-
rone levels independent of its weight-reducing effects,
suggesting a role for leptin to inhibit the hypothalamic-
pituitary-adrenal axis (16). When rats are adrenalecto-
mized, the ability of intracerebroventricular administra-
tion of leptin to reduce food intake and body weight is
enhanced. This increase in sensitivity can be reversed by
glucocorticoid replacement, suggesting that glucocorti-
coids play a physiological role to attenuate the response to
leptin (2).
One potential mechanism whereby glucocorticoids can
influence leptin action is via effects on intracellular signal
transduction pathways activated by leptin in the brain
(17). For example, ADX increases hypothalamic expres-
sion of leptin receptor and signal transducer and activator
of transcription (STAT)-3 while it decreases expression of
suppressor of cytokine signaling (SOCS)-3, an endogenous
inhibitor of leptin receptor signaling. Thus, glucocorticoid
deficiency is proposed to enhance leptin activation of the
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Janus kinase (JAK)-STAT signaling pathway in key hypo-
thalamic neurons and thereby potentiate its feeding effects
(17).
Effects of leptin on food intake and body weight appear
to be mediated in part by the hypothalamic melanocortin
(MC) system (18). MCs (including -melanocyte–stimulat-
ing hormone [-MSH]) are cleavage products of proopio-
melanocortin (POMC), which is synthesized by neurons in
the ARC. These neurons express the long form of the
leptin receptor (13), are activated by leptin, and project to
other nuclei within the hypothalamus, including the para-
ventricular nucleus (PVN) (19), where MC3 and MC4
receptors are located (20–22). Central administration of
-MSH (23,24), or its synthetic analog, melanotan II
(MTII), dose dependently reduces food intake in rodents
(25,26), and endogenous melanocortin signaling is re-
quired for normal body weight regulation (18,27,28)
The effects of -MSH are opposed by agouti-related
protein (AgRP), an endogenous antagonist of MC3 and
MC4 receptors (29) synthesized in ARC neurons that also
synthesize neuropeptide Y. Glucocorticoids are implicated
as negative regulators of melanocortin signaling because
ADX reduces AgRP expression in the hypothalamus of
normal mice and normalizes hypothalamic levels of POMC
mRNA and AgRP mRNA in ob/ob mice (30). Thus, glu-
cocorticoids may influence energy homeostasis via effects
on neural systems downstream of the leptin receptor.
To confirm and extend the finding that central leptin
sensitivity is heightened by the absence of glucocorticoids,
we first performed a full dose-response curve for third
ventricular (i3vt) leptin in ADX rats and sham-operated
controls. To determine whether the absence of glucocor-
ticoids also increases the hypophagic effects of a melano-
cortin agonist, we next performed a dose-response
analysis of i3vt MTII on food intake in ADX rats and
controls. In a separate group of rats, we also determined
whether endogenous glucocorticoids promote the orexi-
genic actions of central AgRP. In a final set of studies, we
examined the influence of glucocorticoids on the expres-
sion of MC4R mRNA. Because ADX causes a deficiency of
circulating hormones in addition to glucocorticoids, in
each of these experiments we also tested the ability of
glucocorticoid replacement to reverse the effects of ADX.
RESEARCH DESIGN AND METHODS
Male Long-Evans rats weighing between 348 and 471 g were obtained from the
breeding colony maintained by the Department of Psychology at the Univer-
sity of Washington or from Harlan (Indianapolis, IN) and housed at the
University of Cincinnati. Rats were housed individually in clear, plastic cages
with ad libitum access to pelleted rat diet (unless otherwise specified) and
water in a temperature-controlled vivarium on a 12:12-h light:dark schedule.
After ADX surgery, all animals had access to a 0.9% NaCl solution in addition
to their water. The research with animals for all studies presented here was
conducted in Association for Assessment and Accreditation of Laboratory
Animal Care–approved facilities, conformed to federal National Institutes of
Health and U.S. Department of Agriculture regulations, and was conducted
with approval of our local Animal Care and Use Committee.
Procedures
i3vt cannulation. Animals were surgically implanted with a 22-gauge (Plas-
tics One, Roanoke, VA) cannula with its tip in the third cerebral ventricle as
previously described (31). Rats were anesthetized with ketamine (86 mg/kg
i.p.)/xylazine (12.9 mg/kg). Verification of cannula placement was accom-
plished by i3vt injection of 10 ng of angiotensin II in 1 l 0.9% saline. Animals
that did not drink 5 ml of water within 60 min after this treatment were not
included in the experiments.
ADX. A short incision was made in the skin rostral to each kidney. The
perirenal fat and prominent adrenal veins were located, and both adrenals
were isolated from the surrounding fat capsule and removed. Animals were
allowed to recover for at least 10 days before experiments began. Because
ADX also removes the mineralocorticoids that are necessary for sodium
retention, all ADX animals had access to isotonic (0.9%) saline in addition to
tap water. To maintain a balanced design, sham animals also had access to
both of these fluids. ADX was verified by measuring plasma corticosterone
levels by radioimmunoassay (RIA). Tail blood was sampled after the comple-
tion of behavioral testing at 1 h before lights off (100 l from the tip of the tail)
for determination of plasma corticosterone levels. Animals with plasma levels
1 g/dl were removed from the study.
Corticosterone RIA. Plasma corticosterone levels were determined by RIA
using rabbit antiserum raised against corticosterone-21-hemisuccinate (B3-
163; Endocrine Sciences, Tarzana, CA). Assay sensitivity was 0.5 g/dl, and
the intra-assay coefficient of variation was between 2 and 5% for all experi-
ments.
Plasma leptin, insulin, and glucose. Glucose was measured using a
glucose oxidase method. Insulin was determined by a previously described
RIA (32). Leptin values were determined using a commercially available RIA
kit (Linco Research, St. Charles, MO).
Experiment 1: Effect of ADX on the feeding response to leptin
Behavioral procedures. Rats (sham, n  14; ADX, n  12) were adapted to
a schedule in which food was removed from the cages, and the animals were
weighed 3 h before the end of the light cycle. On experimental days, 45 min
after food was removed, each animal was injected i3vt with 2 l of recombi-
nant human leptin (Calbiochem, San Diego, CA) dissolved in artificial cere-
brospinal fluid or artificial cerebrospinal fluid alone via a Hamilton syringe.
Food was returned 45 min before lights out, and the food hopper was weighed
after 24 h. Each animal received four treatments (0, 0.35, 1, and 3.5 g of
leptin), with the order counterbalanced across subjects using a Latin-square
procedure. There were at least 3 days with no injections between experimen-
tal days.
Experiment 2: Effect of ADX on the response to leptin in corticoste-
rone-replaced rats
Procedures. ADX animals had their saline drinking fluid replaced with a
solution of 0.9% saline, 2.7 mg/ml corticosterone, and 0.5% alcohol to keep the
corticosterone in solution. Providing ADX rats with this corticosterone
solution results in plasma corticosterone levels comparable with those of
sham-operated controls (33). Rats had access to this solution for 5 days before
any behavioral testing. Food intake was subsequently determined after 24 h
for both groups of rats (sham, n  12; ADX, n  11) following i3vt
administration of either 3.5 g of leptin or artificial cerebrospinal fluid, with
order of treatments counterbalanced across subjects. Tail blood was sampled
after the completion of behavioral testing at 1 h before lights off (100 l from
the tip of the tail) for determination of plasma corticosterone levels.
Experiment 3: Effect of ADX on the feeding response to a melanocortin
agonist
Procedures. Surgical procedures and verifications were performed as de-
scribed for experiment 1. All ADX animals maintained plasma corticosterone
levels 1 g/dl.
Behavioral procedures. Rats (sham, n  8; ADX, n  9) were adapted to a
schedule in which food was removed from the cages 4 h before the end of the
light cycle. On experimental days, 3 h after food was removed, all animals
received an i3vt infusion of 2 l of either MTII (Phoenix Pharmaceuticals,
Mountain View, CA) dissolved in 0.9% saline or saline alone via a Hamilton
syringe. Food was returned at the time of lights out, and the food hopper was
weighed after 1, 4, and 24 h. Each animal received four doses of MTII (0, 0.1,
0.3, and 1.0 nmol), with the order counterbalanced across subjects using a
Latin-square procedure. Animals were allowed at least 3 days without
injections between experimental days.
Experiment 4: Effect of ADX on the feeding response to a melanocortin
agonist in corticosterone-replaced rats
Procedures. ADX animals had their saline drinking fluid replaced with a
corticosterone solution as described in experiment 2. Rats had access to this
solution for 5 days before any behavioral testing. On the day before the
beginning of behavioral testing, all rats had a 100-l tail blood sample 1 h
before lights off for determination of plasma corticosterone by RIA. Both
groups of rats (sham, n  8; ADX, n  7) were then observed for their food
intake response to 0.3 nmol of MTII and saline, with order of the conditions
counterbalanced across subjects.
Experiment 5: Effect of ADX on the feeding response to AgRP
Procedures. Surgical procedures and verifications were performed as de-
scribed for experiment 1. All ADX animals maintained plasma corticosterone
levels 1 g/dl.
Behavioral procedures. Rats (sham, n  15; ADX, n  16) were adapted to
a schedule in which food was removed from the cages 5 h before the end of
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the light cycle. On experimental days, 1 h after food was removed, all animals
received an i3vt infusion of 2 l of either AgRP (Phoenix Pharmaceuticals)
dissolved in 0.9% saline or saline alone via a Hamilton syringe. Food was
returned immediately after injection, and the food hopper was weighed after
4, 24, and 48 h. Each animal received three doses of AgRP (0, 0.1, and 1.0
nmol), with the order counterbalanced across subjects using a Latin-square
procedure. Animals were allowed at least 3 days without injections between
experimental days.
Experiment 6: Effect of ADX on the response to AgRP in corticoste-
rone-replaced rats
Procedures. ADX animals had their normal saline drinking fluid replaced
with a corticosterone solution as described in experiment 2. Rats had access
to this solution for 5 days before any behavioral testing. The day before the
beginning of behavioral testing, all rats had a 100-l tail blood sample taken
1 h before lights off for determination of plasma corticosterone by RIA. Both
groups of rats (sham, n  12; ADX, n  14) were then observed for their food
intake response to 0.1 nmol of AgRP and saline, with order of the conditions
counterbalanced across subjects.
Experiment 7: Effect of ADX and corticosterone replacement on
hypothalamic MC4 receptor expression
Procedures. Half of a group of ADX animals had their corticosterone solution
replaced with a 0.9% saline solution, so that there were three groups of rats for
PCR analysis: sham (n  12), ADX (n  7), and ADX  CORT (n  7). All
animals were killed 1 h before lights out by brief exposure to CO2 followed by
rapid decapitation and removal of fresh brain tissue. Blood samples were also
collected for the later determination of plasma leptin, insulin, and glucose.
RNA isolation and cDNA synthesis. Brains were rapidly removed after
decapitation and placed in RNA Later (Ambion, Austin, TX). Hypothalami
were dissected, and total RNA was extracted using TRI Reagent (Molecular
Research Center, Cincinnati, OH). The Superscript first-strand synthesis
system (Invitrogen, Carlsbad, CA) was used to synthesize cDNA from 5 g of
total RNA.
Semiquantitative expression of MC4R mRNA. A primer and probe set
was designed to amplify a portion of the rat MC4R gene (accession U67863)
using MGB Eclipse Design Software 3.0 from Epoch Biosciences (available at
www.epochbio.com). Primer sequences from 5 to 3 were CAGTGTTTCTT
TCCATGTTAT and CTGTGGGGTGATGCAAT. A FAM-labeled probe com-
posed of the sequence (5 to 3) TTGTTCTTTCTGTGGT was used for
detection of the PCR product. The probe also included a MGB and the Eclipse
dark quencher. A standard curve (R2  0.99) was calculated using a dilution
series spanning four orders of magnitude and the efficiency (E  95%) of the
reaction calculated from the slope of the plot threshold cycle (CT) versus log
starting concentration. Samples were run in triplicate and normalized to
constitutively expressed ribosomal protein L32.
Statistics. Food intake data for experiment 1 were analyzed using a repeated
measures two-way ANOVA, and food intake data for experiments 3 and 5 were
analyzed using three-way (surgery  drug  time point) repeated-measures
ANOVA. Experiments 2 and 7 were analyzed using one-way ANOVAs, and
experiments 4, 6, and 7 were analyzed using two-way ANOVAs. Plasma values
in experiment 7 were analyzed using one-way ANOVA. All pairwise compar-
isons of mean differences were conducted using Tukey honestly significant
difference post hoc comparisons. Differences between group means were
considered statistically significant if P  0.05.
RESULTS
Experiment 1. There was a significant main effect of
leptin dose on food intake at 24 h in both ADX and
sham-operated rats (P  0.05 in both cases). Leptin
administration reduced food intake to a greater extent in
ADX animals than sham animals at all doses tested (P 
0.05 in each case) at 24 h (Table 1). When assessed as the
absolute change in food intake from when the animals
were injected with vehicle, leptin only reduced food intake
to a significantly greater extent in ADX compared with
sham animals at the 3.5-g dose (P  0.05) (Fig. 1).
Experiment 2. Plasma corticosterone concentrations
were significantly reduced (to undetectable levels) in ADX
compared with sham animals (6.4 	 1.5 g/dl) when
assessed 1 h before lights out (P 0.05). ADX animals that
had corticosterone replaced in their drinking water (ADX
 CORT) had plasma corticosterone concentrations sim-
ilar to sham animals (5.8 	 1.1 g/dl) (P  0.05). Ex-
pressed as a percentage of each animal’s own vehicle
intake, administration of 3.5 g leptin significantly re-
duced food intake in both sham and ADX CORT animals
(P  0.05 in both cases). Leptin reduced food intake to a
similar extent in sham and ADX  CORT animals (P 
0.05). Relative to vehicle-treated controls, i3vt leptin re-
duced intake to a greater extent in ADX animals compared
with both sham and ADX  CORT animals (P  0.05 in
both cases) (Fig. 2).
Experiment 3. There was a significant effect of MTII dose
on food intake at 1, 4, and 24 h in both sham and ADX
animals (P  0.05 in all cases). MTII reduced food intake
to a greater extent in ADX animals compared with sham
animals at all doses of MTII at 4 h (P  0.05 in all cases),
at 0.1 and 0.3 nmol at 1 h, and at 1.0 nmol at 24 h (P  0.05
in all cases), although there were no significant interac-
tions (Table 2). When assessed as the absolute change in
food intake from when the animals were injected with
vehicle, the 4-h intake was significantly reduced in ADX
compared with sham animals at the 0.1 and 0.3 nmol doses
(P  0.05) but not at the 1.0 nmol dose (P  0.05) (Fig. 3).
MTII significantly reduced body weight at all doses com-
pared with vehicle injections in both sham and ADX
animals (P  0.05 in all cases), but there were no differ-
ences in this reduction between surgery groups (P  0.05)
(e.g., at the 0.3-nmol MTII dose, 24-h body weight change
FIG. 1. Mean  SE 24-h food intake in rats that received either
bilateral ADX or sham surgery and were treated i3vt with leptin or
vehicle. Data are represented as absolute change from when animals
were injected with vehicle. f, sham; , ADX. *Significantly different
from paired sham (P < 0.05).
TABLE 1
Food intake (24 h) in rats treated i3vt with leptin
Leptin dose (g) Sham ADX
Vehicle 26.0 	 1.20 19.2 	 2.20*
0.35 22.1 	 1.10 12.3 	 1.68*
1.0 18.8 	 1.41 8.7 	 1.20*
3.5 16.8 	 1.32 5.32 	 0.80*
Data are means 	 SE. *Significantly different from sham at the same
time point and leptin dose.
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in sham was 
25.69 	 2.34 g and in ADX was 
21.49 	
2.47).
Experiment 4. Plasma corticosterone concentrations
were significantly reduced (to undetectable levels) in ADX
compared with sham animals (6.46 	 0.79 g/dl) when
assessed at 1 h before lights out (P  0.05). ADX  CORT
animals had plasma corticosterone concentrations similar
to sham animals (7.6 	 0.85 g/dl) (P  0.05). Adminis-
tration of 0.3 nmol MTII reduced food intake comparably
in both sham and ADX  CORT animals (P  0.05 in both
cases). MTII significantly reduced food intake in both
groups (P 0.05) and to a similar extent in sham and ADX
 CORT animals (P  0.05) (Fig. 4).
Experiment 5. There was a significant effect of AgRP at
both 0.1 and 1.0 nmol on food intake at 24 and 48 h in sham
animals (P  0.05 in all cases) but not at 4 h (P  0.05). In
ADX animals, however, AgRP was ineffective in increasing
food intake at 0.1 and 1.0 nmol at all time points measured
(P  0.05) (Fig. 5 shows 24-h data, and Table 3 shows the
other time points). AgRP significantly increased body
weight at both doses in sham animals (P  0.05 in both
cases) but not in ADX animals (P  0.05 in both cases)
(e.g., at the 0.1-nmol AgRP dose, 24-h body weight change
in sham was 20.40 	 4.7 g and in ADX was 1.76 	 4.7 g).
Experiment 6. Plasma corticosterone concentrations
were significantly reduced (to undetectable levels) in ADX
compared with sham animals (10.7 	 1.7 g/dl) when
assessed at 1h before lights out (P  0.05). ADX  CORT
animals had plasma corticosterone concentrations similar
to sham animals (6.3 	 2.8 g/dl) (P  0.05). Administra-
tion of 0.1 nmol AgRP significantly increased food intake
in both sham and ADX  CORT animals (P  0.05 in both
cases). AgRP increased food intake to a similar extent in
sham and ADX  CORT animals (P  0.05) (Fig. 6).
Experiment 7. Mean 	 SE expression of MC4 receptor
relative to L32 control was similar across sham (52.43 	
5.79), ADX (65.42 	 10.90), and ADX  CORT (44.17 	
3.35) groups (P  0.05). ADX animals had significantly
lower plasma leptin, insulin, and glucose compared with
sham animals (leptin: 8.87 	 1.14 vs. 1.98 	 0.36 ng/ml;
insulin: 428.30 	 44.71 vs. 174.67 	 21.05 pmol/l; glucose:
10.19 	 0.42 vs. 8.23 	 0.31 mmol/l; for sham and ADX,
respectively) (P  0.05 in all cases).
DISCUSSION
ADX has long been known to have antiobesity effects in
rodents, and more recently, these effects have been attrib-
uted to a sensitization of leptin action (2). Consistent with
previous findings, we report that ADX reduced spontane-
ous food intake and enhanced the ability of i3vt leptin to
reduce food intake and that replacement of glucocorti-
coids reversed this effect (17). The removal of glucocorti-
coids had a similar effect to augment the anorectic action
of i3vt MTII, and this effect was reversed by glucocorticoid
replacement. Conversely, the orexigenic action of i3vt
AgRP was completely absent in ADX animals compared
with sham animals, and this effect was again reversed by
FIG. 2. Mean  SE 24-h food intake in rats that received either ADX or
sham surgery or that received ADX surgery and 5 consecutive days of
corticosterone in the drinking water (2.7 mg/ml) and were treated i3vt
with 3.5 g leptin or vehicle. Data are represented as the percentage of
each group’s mean vehicle intake. f, sham; , ADX; o, ADX  CORT.
*Significantly different from ADX (P < 0.05).
FIG. 3. Mean  SE 4-h food intake in rats that received either ADX or
sham surgery and were treated i3vt with MTII or vehicle. Data are
represented as absolute change from when animals were injected with
vehicle. f, sham; , ADX. *Significantly different from paired sham
(P < 0.05).
TABLE 2
Food intake (1, 4, and 24 h) in rats treated i3vt with MTII
MTII dose (nmol) Sham (1 h) ADX (1 h) Sham (4 h) ADX (4 h) Sham (24 h) ADX (24 h)
Vehicle 3.04 	 0.33 2.36 	 0.31 5.88 	 0.46 4.98 	 0.44 24.00 	 1.49 22.41 	 1.41
0.1 1.84 	 0.36 0.33 	 0.38* 3.09 	 0.51 0.56 	 0.52* 15.88 	 1.63 8.91 	 1.68
0.3 1.94 	 0.34 0.39 	 0.38* 2.81 	 0.51 0.48 	 0.52* 9.54 	 1.61 5.49 	 1.70
1.0 0.54 	 0.33 0.66 	 0.35 2.33 	 0.47 1.21 	 0.44 11.4 	 1.45 4.89 	 1.41*
Data are means 	 SE. *Significantly different from sham at the same time point and MTII dose.
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glucocorticoid replacement. Finally, there was a nonsig-
nificant trend for MC4R mRNA to be upregulated in ADX
compared with sham animals. These data support other
studies, suggesting an interaction between glucocorticoids
and the melanocortin system. For example, some (but not
all) studies (30,34,35) have reported that ADX decreases
hypothalamic POMC and AgRP mRNA. Collectively, these
data suggest that the opposing actions of glucocorticoids
on leptin action in the brain are likely to involve effects
mediated, at least in part, downstream of the leptin
receptor and via interactions with the melanocortin sys-
tem and its targets to influence food intake and body
weight.
Consistent with previous work (2), the present data
suggest that endogenous glucocorticoids render an indi-
vidual less sensitive to the anorectic effects of leptin. One
proposed explanation for this effect is that glucocorticoids
inhibit leptin action by altering expression of leptin recep-
tor and/or downstream signaling molecules such as
STAT-3 and SOCS-3 (17). The increase in leptin receptor
expression could be due in part to the decrease in plasma
leptin observed in ADX rats. Recent data also indicate an
important role for phosphatidylinositol 3-kinase in leptin’s
ability to reduce food intake, opening up another intracel-
lular signaling pathway that glucocorticoids may act upon
to alter the response to leptin (36).
A key finding of the current study is that regardless of
the effects that glucocorticoids may have on the cellular
response to leptin receptor activation, they also may
reduce leptin sensitivity by acting downstream at the level
of the central nervous system melanocortin system. One
possible mechanism to explain these effects is to propose
that glucocorticoids reduce either the abundance or re-
sponsiveness of MC4 receptors, which are concentrated in
key hypothalamic areas such as the PVN (37). The present
data suggest that MC4 receptor mRNA may be upregulated
FIG. 4. Mean  SE 4-h food intake in rats that received either sham
surgery or that received ADX surgery and 5 consecutive days of
corticosterone in drinking water (2.7 mg/ml) and were treated i3vt
with 0.3 nmol MTII or vehicle. f, sham;, ADX  CORT. *Significantly
different from saline-treated rats (P < 0.05).
FIG. 5. Mean  SE 24-h food intake in rats that received either ADX or
sham surgery and were treated i3vt with AgRP or vehicle. f, sham; ,
ADX. *Significantly different from paired sham (P < 0.05).
FIG. 6. Mean  SE 24-h food intake in rats that received either sham
surgery or that received ADX surgery and 5 consecutive days of
corticosterone in drinking water (2.7 mg/ml) and were treated i3vt
with 0.1 nmol AgRP or vehicle. f, sham;, ADX CORT. *Significantly
different from saline-treated rats (P < 0.05).
TABLE 3
Food intake (4 and 48 h) in rats treated i3vt with AgRP
AgRP
dose
(nmol) Sham (4 h) ADX (4 h) Sham (48 h) ADX (48 h)
Vehicle 2.85 	 1.25 2.78 	 1.28 58.05 	 6.91 42.45 	 4.78
0.1 8.78 	 1.12 3.80 	 1.02* 77.89 	 6.14 38.47 	 5.32*
1.0 8.65 	 1.44 3.68 	 1.52* 81.53 	 7.99 50.83 	 6.92*
Data are means 	 SE. *Significantly different from sham at the same
time point and AgRP dose.
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in ADX animals compared with sham animals, which
would account for the increased sensitivity to MTII in ADX
animals. MC4 receptor activity could also be upregulated
without significant changes in gene expression. Alterna-
tively, glucocorticoids could alter the central nervous
system melanocortin system via action on ARC neurons to
alter the release of either -MSH or AgRP. The levels of
endogenous ligands for the MC4 receptor can influence the
ability of exogenous compounds to bind and alter the
activity of MC4 receptor signaling. Although the finding is
controversial, ADX has been demonstrated to increase
POMC mRNA (34), suggesting that glucocorticoids nor-
mally inhibit POMC tone. Others, however, have reported
(38) that POMC mRNA in the medial basal hypothalamus
is decreased after ADX, which would be consistent with a
compensatory upregulation of MC4 receptor activity. Con-
sistent with ADX increasing melanocortin tone, ADX re-
duces hypothalamic AgRP mRNA without affecting serum
leptin concentrations (30), suggesting that glucocorticoids
might increase the activity of AgRP neurons. Thus after
ADX, less AgRP would be available to occupy MC4 recep-
tors, making exogenous MTII more capable of binding and
activating MC4 receptors.
Interestingly, glucocorticoid deficiency had potent ef-
fects on the ability of both MTII to reduce food intake and
AgRP to increase food intake. Teleologically, such results
make sense because both results are likely to bias the
animal to consume less food and gain less weight, such as
occurs after ADX. However, these results are not easily
explained by a single effect of glucocorticoids directly on
MC4 receptor expression or activity. Moreover, such re-
sults also cannot be the result of simply changing levels of
-MSH or AgRP in the synapse. We would like to offer a
potential mechanism for glucocorticoid action that in-
volves influencing the actions of syndecan-3 in the PVN.
The syndecans are a family of highly abundant cell-surface
heparin sulfate proteoglycans that are able to bind many
extracellular peptides (39). Evidence suggests that synde-
can-3 acts as a coreceptor for AgRP, normally facilitating
the action of AgRP at melanocortin receptors. During
fasting, syndecan-3 is predominately in the active mem-
brane-bound form where it can facilitate the actions of
AgRP to reduce melanocortin signaling (40). If membrane-
bound syndecan-3 is increased by glucocorticoids, its
absence could be predicted to increase the actions of MC4
receptor agonists while simultaneously reducing the effi-
cacy of AgRP. At this point, this possibility remains
speculation, and future research is needed to address
whether glucocorticoids regulate both the expression and
membrane status of syndecan-3 within the PVN.
It is not necessarily inconsistent, however, that ADX
animals were both more sensitive to MTII and insensitive
to AgRP. MC4R knockout mice do not respond to MTII,
suggesting that MTII is acting primarily on MC4 receptors
rather than on MC3 receptors (41). On the other hand,
AgRP is effective in these knockouts, indicating that AgRP
does not require the MC4 receptor, and may be acting at
the MC3 receptor (41) or via an unidentified mechanism
independent of competitive antagonism at the MC4 recep-
tor (42).
Glucocorticoids exert myriad effects on behavior and
physiology, and glucocorticoid receptors are widespread
throughout the central nervous system and periphery (43).
Glucocorticoid receptors are present in regions of the
hypothalamus important for the regulation of food intake
and body weight, including the ARC, PVN, and lateral
hypothalamus (43). Therefore, it is likely that glucocorti-
coids influence the activity or responsiveness to numerous
neuropeptide systems in addition to the leptin-melanocor-
tin system, and as previously reported, insulin and neu-
ropeptide Y (44,45). The current data suggest that the
important effects that glucocorticoids exert to alter food
intake and energy balance involve significant actions on
the melanocortin system. Future studies will need to
investigate the role of specific glucocorticoid receptor
populations in these effects on food intake and body
weight to elucidate the complicated circuitry by which
glucocorticoids influence energy balance.
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